Product Name
SLC26A2, siRNA
Full Product Name
SLC26A2 siRNA (Mouse)
Product Synonym Names
DTD; DTDST; Sulfate transporter; Diastrophic dysplasia protein homolog; ST-OB; Solute carrier family 26 member 2
Product Gene Name
SLC26A2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q62273
Specificity
SLC26A2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse SLC26A2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SLC26A2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SLC26A2 sirna
siRNA to inhibit SLC26A2 expression using RNA interference
Applications Tested/Suitable for SLC26A2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SLC26A2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_031911.1
[Other Products]
NCBI GenBank Nucleotide #
NM_007885.2
[Other Products]
UniProt Primary Accession #
Q62273
[Other Products]
UniProt Secondary Accession #
Q543D6; Q8R2L9[Other Products]
UniProt Related Accession #
Q62273[Other Products]
Molecular Weight
81,604 Da
NCBI Official Full Name
sulfate transporter
NCBI Official Synonym Full Names
solute carrier family 26 (sulfate transporter), member 2
NCBI Official Symbol
Slc26a2??[Similar Products]
NCBI Official Synonym Symbols
Dtd; ST-OB
??[Similar Products]
NCBI Protein Information
sulfate transporter
UniProt Protein Name
Sulfate transporter
UniProt Synonym Protein Names
Diastrophic dysplasia protein homolog; ST-OB; Solute carrier family 26 member 2
Protein Family
Sulfate transporter
UniProt Gene Name
Slc26a2??[Similar Products]
UniProt Synonym Gene Names
Dtd; Dtdst??[Similar Products]
UniProt Entry Name
S26A2_MOUSE
UniProt Comments for SLC26A2
SLC26A2: Sulfate transporter. May play a role in endochondral bone formation. Defects in SLC26A2 are the cause of diastrophic dysplasia (DTD). DTD is an autosomal recessive disease characterized by osteochondrodysplasia with clinical features including dwarfism, spinal deformation, and specific joint abnormalities. Defects in SLC26A2 are the cause of achondrogenesis type 1B (ACG1B). ACG1B is a recessively inherited chondrodysplasia characterized by extremely poor skeletal development and perinatal death. Defects in SLC26A2 are the cause of atelosteogenesis type 2 (AO2); also known as neonatal osseous dysplasia 1. AO2 is characterized by severely shortened limbs, small chest, scoliosis, club foot of the equinovarus type (talipes equinovarus), abducted thumbs and great toes, and cleft palate. Patients die of respiratory insufficiency shortly after birth because of the collapse of the airways and pulmonary hypoplasia due to the small rib cage. Defects in SLC26A2 are the cause of multiple epiphyseal dysplasia type 4 (EDM4). EDM is a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. EDM is broadly categorized into the more severe Fairbank and the milder Ribbing types. EDM4 is a recessively inherited form, characterized by early childhood-onset hip dysplasia and recurrent patella dislocation. Short stature in EDM4 patients is not frequent. Belongs to the SLC26A/SulP transporter (TC 2.A.53) family.
Protein type: Membrane protein, integral; Membrane protein, multi-pass; Transporter; Transporter, SLC family
Cellular Component: membrane; integral to membrane
Molecular Function: sulfate transmembrane transporter activity; secondary active sulfate transmembrane transporter activity
Biological Process: ossification; transport; sulfate transport; ion transport; transmembrane transport
Research Articles on SLC26A2
1. Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal cortex and regulates aldosterone secretion.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
